Norgestimate
and Ethinyl Estradiol (Ortho Tri-Cyclen)
Category:
Description:
Indications:
Contraindications:
-
Pregnancy
-
Undiagnosed
abnormal vaginal bleeding
-
Known
or suspected benign or malignant liver tumors while on oral
contraceptive use
- Breast carcinoma or estrogen-dependent neoplasia
-
Current
or history of thromboembolic disorders, cerebral vascular or
cardiovascular disease.
Precautions:
-
Pregnancy
category X
-
Take
as directed at intervals not exceeding 24 hours. Effectiveness is dependent upon strict compliance.
-
OCPs
are 99.9% effective after the 1st month, if taken according to the
prescribed schedule.
-
During
the first month, effectiveness depends on how many OCPs have been
taken, but overall are about 95% effective, comparable to condoms or a
diaphragm.
-
Breakthrough
bleeding (“spotting”) may occur during initiation of therapy.
-
Instructions
for missed doses:
-
One
missed dose: Take as soon as possible or two tablets the next day
and continue
-
Two
missed doses: Take two tablets daily for two days, then continue
normal schedule
-
Three
missed doses: Discontinue therapy and begin new packet 7 days
following last dose
-
May
cause mental depression, fluid retention and depressed folate levels
-
Twenty-eight
day packs contain seven days of inert ingredients to maintain regimen
Adverse
Reactions (Side Effects):
-
Abdominal
cramping, anorexia, nausea, vomiting
-
Acne
(Usually makes it better)
-
Breast
tenderness
-
Edema,
weight gain
-
Unusual
tiredness or weakness
-
Cardiovascular
disorders (hypertension)
-
Thromboembolic
disorders
|
Dosage:
For
more information on Oral Contraceptive Pills, read:
|
Home
· Military Medicine
· Sick Call · Basic Exams
· Medical Procedures
· Lab and X-ray · The Pharmacy
· The Library · Equipment
· Patient Transport
· Medical Force
Protection · Operational Safety · Operational
Settings · Special
Operations · Humanitarian
Missions · Instructions/Orders · Other Agencies · Video Gallery
· Forms · Web Links · Acknowledgements
· Help · Feedback Approved for public release;
Distribution is unlimited. The information contained here is an abbreviated summary. For more detailed and complete information, consult the manufacturer's product information sheets or standard textbooks.
Source: Operational Medicine 2001, Health Care in Military Settings, NAVMED P-5139, May 1, 2001, Bureau of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington, D.C., 20372-5300.
Bureau of Medicine and Surgery
Department of the Navy
2300 E Street NW
Washington, D.C
20372-5300 |
Operational Medicine
Health Care in Military Settings
CAPT Michael John Hughey, MC, USNR
NAVMED P-5139
January 1, 2001 |
United States Special Operations
Command
7701 Tampa Point Blvd.
MacDill AFB, Florida
33621-5323 |
*This web version is provided by The Brookside Associates, LLC. It contains
original contents from the official US Navy NAVMED P-5139, but has been
reformatted for web access and includes advertising and links that were not
present in the original version. The medical information presented was reviewed and felt to be accurate in 2001. Medical knowledge and practice methods may have changed since that time. Some links may no longer be active. This web version has not been approved by the
Department of the Navy or the Department of Defense. The presence of any
advertising on these pages does not constitute an endorsement of that product or
service by either the US Department of Defense or the Brookside Associates. The
Brookside Associates is a private organization, not affiliated with the United
States Department of Defense.
© 2015, Brookside Associates, LLC. All rights reserved
Other Brookside Products
|
|